[HTML][HTML] Clinical spectrum, genetic complexity and therapeutic approaches for retinal disease caused by ABCA4 mutations

FPM Cremers, W Lee, RWJ Collin… - Progress in retinal and eye …, 2020 - Elsevier
The ABCA4 protein (then called a “rim protein”) was first identified in 1978 in the rims and
incisures of rod photoreceptors. The corresponding gene, ABCA4, was cloned in 1997, and …

[HTML][HTML] Quantitative approaches in multimodal fundus imaging: state of the art and future perspectives

A Arrigo, E Aragona, MB Parodi, F Bandello - Progress in Retinal and Eye …, 2023 - Elsevier
When it first appeared, multimodal fundus imaging revolutionized the diagnostic workup and
provided extremely useful new insights into the pathogenesis of fundus diseases. The recent …

Inherited retinal degenerations: current landscape and knowledge gaps

JL Duncan, EA Pierce, AM Laster… - … vision science & …, 2018 - tvst.arvojournals.org
Inherited retinal degenerations (IRDs) represent a diverse group of progressive, visually
debilitating diseases that can lead to blindness in which mutations in genes that are critical …

Phenoty** and genoty** inherited retinal diseases: Molecular genetics, clinical and imaging features, and therapeutics of macular dystrophies, cone and cone-rod …

M Georgiou, AG Robson, K Fu**ami… - Progress in retinal and …, 2024 - Elsevier
Inherited retinal diseases (IRD) are a leading cause of blindness in the working age
population and children. The scope of this review is to familiarise clinicians and scientists …

[HTML][HTML] Endpoints for clinical trials in ophthalmology

L Schmetterer, H Scholl, G Garhöfer… - Progress in Retinal and …, 2023 - Elsevier
With the identification of novel targets, the number of interventional clinical trials in
ophthalmology has increased. Visual acuity has for a long time been considered the gold …

Macular dystrophies: clinical and imaging features, molecular genetics and therapeutic options

N Rahman, M Georgiou, KN Khan… - British Journal of …, 2020 - bjo.bmj.com
Macular dystrophies (MDs) consist of a heterogeneous group of disorders that are
characterised by bilateral symmetrical central visual loss. Advances in genetic testing over …

Complement inhibition as a therapeutic strategy in retinal disorders

E Kassa, TA Ciulla, RM Hussain… - Expert opinion on …, 2019 - Taylor & Francis
Introduction: Dry age-related macular degeneration (AMD) and Stargardt Macular Dystrophy
(STGD1) result in vision loss due to progressive atrophy of the macula and lack of effective …

Long-term safety and tolerability of subretinal transplantation of embryonic stem cell-derived retinal pigment epithelium in Asian Stargardt disease patients

Y Sung, MJ Lee, J Choi, SY Jung, SY Chong… - British Journal of …, 2021 - bjo.bmj.com
Background Although human embryonic stem cells (hESCs) have been considered a
potential therapeutic option for regenerative medicine, there are some concerns regarding …

Progression of Stargardt disease as determined by fundus autofluorescence over a 12-month period: ProgStar report no. 11

RW Strauss, X Kong, A Ho, A Jha, S West… - JAMA …, 2019 - jamanetwork.com
Importance Sensitive outcome measures for disease progression are needed for treatment
trials of Stargardt disease. Objective To estimate the progression rate of atrophic lesions in …

Stargardt disease and progress in therapeutic strategies

D Huang, RC Heath Jeffery, MT Aung-Htut… - Ophthalmic …, 2022 - Taylor & Francis
Background Stargardt disease (STGD1) is an autosomal recessive retinal dystrophy due to
mutations in ABCA4, characterized by subretinal deposition of lipofuscin-like substances …